Earnings ·
PMV Pharma reports Q3 net loss of $34.4M, announces closing of $50 million public offering
PMVPPMV Pharmaceuticals, Inc.
PMV Pharmaceuticals reported a third-quarter 2026 net loss of $34.4 million, an increase from $21.1 million in the prior-year period, driven by a $12.8 million non-cash loss related to warrant liability fair value changes and offering costs. The company ended the quarter with $108.5 million in cash, cash equivalents, and marketable securities, providing a runway into early 2028 following the closing of an oversubscribed $50 million public equity offering completed in August. Corporate highlights include the completion of enrollment for the primary analysis population in the Phase 2 PYNNACLE trial for rezatapopt and the appointment of new board member Matt Eckler and Chief Commercial Officer Philip Herman. PMV Pharmaceuticals is a precision oncology company pioneering small molecule therapies targeting p53.